Statistical Analysis Plan for the Treatment of Cardiovascular disease with low dose Rivaroxaban in Advanced CKD (TRACK) trial
Billot, L.; Wong, M. G.; De Vriese, A.; Collister, D.; Flahault, A.; Mushahar, L.; Ramachandran, R.; Skhiri, H.; Shaman, A.; Menne, J.; Gallagher, M.
Show abstract
1The Treatment of cardiovascular disease with low dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) trial is a randomised quadruple-blind phase IV clinical trial to determine whether low-dose rivaroxaban (2.5 mg daily) reduces the risk of major adverse cardiovascular events compared to placebo. It aims to recruit approximately 2,000 patients with advanced chronic kidney disease (stages 4, 5 or dialysis-dependent) and an elevated cardiovascular risk. This statistical analysis plan pre-specifies the method of analysis for every outcome and key variable collected in the trial. The primary outcome is the time from randomisation to first occurrence of major cardiovascular event including death from cardiovascular cause, myocardial infarction, stroke or peripheral artery disease event. The primary analysis will consist in a Cox proportional hazard model adjusted for stratification variables. The analysis plan also includes planned sensitivity analyses including covariate adjustments and subgroup analyses.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: a structured protocol 93%
- Randomised, controlled, feasibility trial comparing vasopressor infusion administered via peripheral cannula versus central venous catheter for critically ill adults: a study protocol 93%
- Using numerical modelling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample 92%
Similar papers in this journal
- Real-world effects of ACE inhibitors and Angiotensin Receptor Blockers: protocol for an emulation study of the ONTARGET trial using electronic health records 97%
- ‘Self-Management Intervention through Lifestyle Education for Kidney health’ (the SMILE-K study): protocol for a single-blind longitudinal randomised control trial with nested pilot study 94%
- RESEARCH PROTOCOL: Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus 93%
Similar papers in this journal
- Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial 96%
- Evaluating Diuretics in Normal Care (EVIDENCE): Protocol of a cluster randomised controlled equivalence trial of prescribing policy to compare the effectiveness of thiazide-type diuretics in hypertension. 93%
- Decision support system to evaluate VENTilation in the Acute Respiratory Distress Syndrome (DeVENT study) – Trial Protocol 93%
Similar papers in this journal
- Preprint server use in kidney disease research: a rapid review 91%
- The mediating role of trust in physicians on the association between multidimensional health literacy and medication adherence in hemodialysis: A cross-sectional study 91%
- Comparison of low eGFR prevalence and prediction for mortality using 2009 and 2021 CKD-EPI equations in Mexican adults 90%
Similar papers in this journal
- The Effect of Intradialytic Exercise on Dialysis Patient Survival: A Randomized Controlled Trial 92%
- COVID-19 in patients undergoing renal replacement therapy in Scotland: findings and experience from the Scottish Renal Registry 92%
- Ramadan and Kidney disease (RaK) risk assessment tool. Potential Risk Calculator for Evaluating the Risk of Ramadan Fasting In Chronic Kidney Disease patients 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.